X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (9) 9
animals (7) 7
mice (7) 7
cell biology (6) 6
cell line, tumor (6) 6
antineoplastic agents - pharmacology (4) 4
drug resistance (4) 4
protein kinase inhibitors - pharmacology (4) 4
biochemistry & molecular biology (3) 3
cancer (3) 3
colon-cancer (3) 3
drug resistance, neoplasm (3) 3
expression (3) 3
female (3) 3
identification (3) 3
mutations (3) 3
oncology (3) 3
receptor, epidermal growth factor - genetics (3) 3
receptor, epidermal growth factor - metabolism (3) 3
respiratory tract diseases (3) 3
signal transduction (3) 3
signal transduction - drug effects (3) 3
tumors (3) 3
acquired-resistance (2) 2
adenocarcinoma (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - therapeutic use (2) 2
cell proliferation - drug effects (2) 2
co-repressor (2) 2
dna-binding proteins - genetics (2) 2
dna-binding proteins - metabolism (2) 2
drug resistance, neoplasm - drug effects (2) 2
drug resistance, neoplasm - genetics (2) 2
egfr (2) 2
emt (2) 2
gefitinib (2) 2
gene expression regulation, neoplastic - drug effects (2) 2
growth (2) 2
indoles - pharmacology (2) 2
lung cancer (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - metabolism (2) 2
lung neoplasms - pathology (2) 2
map kinase signaling system (2) 2
melanoma - drug therapy (2) 2
melanoma - genetics (2) 2
melanoma - pathology (2) 2
mitogen-activated protein kinase kinases - antagonists & inhibitors (2) 2
mitogen-activated protein kinase kinases - metabolism (2) 2
neoplasms (2) 2
nuclear proteins - genetics (2) 2
nuclear proteins - metabolism (2) 2
progression (2) 2
protein kinase inhibitors - therapeutic use (2) 2
protein tyrosine phosphatase, non-receptor type 11 - metabolism (2) 2
proteins (2) 2
proto-oncogene proteins b-raf - genetics (2) 2
proto-oncogene proteins b-raf - metabolism (2) 2
proto-oncogene proteins c-met - metabolism (2) 2
raf inhibition (2) 2
receptor (2) 2
rna, small interfering (2) 2
rodents (2) 2
sulfonamides - pharmacology (2) 2
tumor-suppressor (2) 2
tyrosine kinase inhibitors (2) 2
xenograft model antitumor assays (2) 2
13-cis-retinoic acid (1) 1
acrylamides - pharmacology (1) 1
activation (1) 1
aged (1) 1
alcohol oxidoreductases - genetics (1) 1
alcohol oxidoreductases - metabolism (1) 1
allosteric properties (1) 1
amplification (1) 1
anilides - pharmacology (1) 1
animal models (1) 1
article (1) 1
articles (1) 1
atrial function (1) 1
atrial sensing (1) 1
atrial stimulation (1) 1
atrium (1) 1
aug (1) 1
azetidines - pharmacology (1) 1
beta catenin - metabolism (1) 1
biochemistry, genetics and molecular biology (1) 1
biology (1) 1
biopsy (1) 1
body regions (1) 1
braf inhibition (1) 1
braf inhibitor (1) 1
breast cancer (1) 1
breast-cancer (1) 1
c-jun (1) 1
c-met (1) 1
c-met protein (1) 1
cancer-associated fibroblasts - metabolism (1) 1
cancer-associated fibroblasts - pathology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 2014, Volume 508, Issue 1, pp. 118 - 122
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably(1,2).... 
GROWTH-FACTOR RECEPTOR | BRAF INHIBITOR | RAF INHIBITION | CELLS | MULTIDISCIPLINARY SCIENCES | IMPROVED SURVIVAL | DIFFERENTIATION | C-JUN | CANCER | EXPRESSION | EGFR | Receptor, Epidermal Growth Factor - genetics | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Cellular Senescence - drug effects | Melanoma - enzymology | Antineoplastic Agents - administration & dosage | Receptor, Platelet-Derived Growth Factor beta - genetics | Indoles - administration & dosage | Mitogen-Activated Protein Kinase Kinases - metabolism | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | SOXE Transcription Factors - deficiency | Proto-Oncogene Proteins B-raf - metabolism | Receptor, Platelet-Derived Growth Factor beta - metabolism | Receptor, Epidermal Growth Factor - biosynthesis | Gene Library | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Transforming Growth Factor beta - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Receptor Protein-Tyrosine Kinases - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Transforming Growth Factor beta - metabolism | Receptor, Platelet-Derived Growth Factor beta - biosynthesis | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | SOXE Transcription Factors - genetics | Proteins | Biopsy | Rodents | Genes | Melanoma | Mutation | Kinases | Drug resistance | Patients | Tumors | Index Medicus
Journal Article
Cell Reports, ISSN 2211-1247, 09/2015, Volume 12, Issue 12, pp. 1978 - 1985
Most ( ) mutant melanomas are sensitive to selective BRAF inhibitors, but mutant colon cancers are intrinsically resistant to these drugs because of feedback... 
COLON-CANCER | SHP2 PTPN11 | LUNG-CANCER | MEK INHIBITION | BRAF(V600E) INHIBITION | GROWTH | PROTEIN-TYROSINE PHOSPHATASES | RAF INHIBITORS | MUTATIONS | NOONAN-SYNDROME | CELL BIOLOGY | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism | RNA, Small Interfering - genetics | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Colonic Neoplasms - genetics | Colonic Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Genomic Library | ras Proteins - metabolism | Colonic Neoplasms - metabolism | MAP Kinase Signaling System | Receptor, Epidermal Growth Factor - metabolism | Melanoma - genetics | Indoles - pharmacology | Lentivirus - genetics | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Transduction, Genetic | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - antagonists & inhibitors | Melanoma - pathology | Sulfonamides - pharmacology | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Melanoma - drug therapy | Cell Line, Tumor | Mice, Inbred NOD | High-Throughput Nucleotide Sequencing | Mice | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics | Genetic Vectors | Drug Resistance, Neoplasm - drug effects | RNA, Small Interfering - metabolism | Index Medicus
Journal Article
Journal Article
Journal Article
Molecular and Cellular Biology, ISSN 0270-7306, 08/2013, Volume 33, Issue 16, pp. 3063 - 3063
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2018, Volume 24, Issue 7, pp. 954 - 960
The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, is involved in signal transduction downstream of multiple growth... 
MEDICINE, RESEARCH & EXPERIMENTAL | PANCREATIC DUCTAL ADENOCARCINOMA | TYROSINE PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL BIOLOGY | COLON-CANCER | SHP2 | INHIBITION | K-RAS | CELL LUNG-CARCINOMA | MOUSE MODEL | PROGRESSION | PHOSPHOTYROSINE PHOSPHATASE | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism | Pancreatic Neoplasms - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Lung Neoplasms - metabolism | Pancreatic Neoplasms - pathology | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Lung Neoplasms - pathology | Mutation - genetics | Carcinogenesis - metabolism | Disease Progression | Carcinogenesis - pathology | Mitogen-Activated Protein Kinase Kinases - metabolism | Animals | Protein Kinase Inhibitors - therapeutic use | Protein Tyrosine Phosphatase, Non-Receptor Type 11 - deficiency | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Tyrosine | Care and treatment | Cellular signal transduction | Genetic aspects | Research | Gene expression | Cancer | Adenocarcinoma | Animal models | Xenotransplantation | Lung cancer | Phosphatase | Carcinogenesis | K-Ras protein | Proteins | Signal transduction | Carcinogens | Allosteric properties | Clonal deletion | Organoids | Dependence | Xenografts | Deletion | Protein-tyrosine kinase receptors | Inhibition | Pancreas | Protein-tyrosine kinase | MAP kinase | Tumor cell lines | Signaling | Transduction | Tumors | Protein-tyrosine-phosphatase | Index Medicus
Journal Article
Cancer Discovery, ISSN 2159-8274, 2014, Volume 4, Issue 5, pp. 606 - 619
Journal Article
Cell Discovery, ISSN 2056-5968, 09/2016, Volume 2, Issue 1, pp. 16031 - 16031
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical... 
lung cancer | TKI | drug resistance | metabolomics | glutathione | GEFITINIB | GROWTH-FACTOR-RECEPTOR | METABONOMIC ANALYSIS | ACQUIRED-RESISTANCE | TRANSFERASES | IDENTIFICATION | CELL BIOLOGY | TYROSINE KINASE INHIBITORS | MUTATIONS | ETHACRYNIC-ACID | PROGRESSION
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.